Application of 4-(aminomethyl)cyclohexanecarboxylic acid (tranexamic acid; TAMCA) to the central nervous system (CNS) has been shown to result in hyperexcitability and convulsions. However, the mechanisms underlying this action are unknown. In the present study, we demonstrate that TAMCA binds to the ␥-aminobutyric acid (GABA) binding site of GABA A receptors in membranes from rat cerebral cortex and does not interfere with N-methyl-D-aspartate receptors. Patch-clamp studies using human embryonic kidney cells transiently transfected with recombinant GABA A receptors composed of ␣1␤2␥2 subunits showed that TAMCA did not activate these receptors but dose dependently blocked GABA-induced chloride ion flux with an IC 50 of 7.1 Ϯ 3.1 mM. Application of TAMCA to the lumbar spinal cord of rats resulted in dose-dependent hyperexcitability, which was completely blocked by coapplication of the GABA A receptor agonist muscimol. These results indicate that TAMCA may induce hyperexcitability by blocking GABA-driven inhibition of the CNS.
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Tranexamic acid [4-(aminomethyl)cyclohexanecarboxylic acid; TAMCA; molecular weight 157.2] is a synthetic lysine analog that shows high affinity for the lysine binding sites of plasminogen and plasmin. As such, TAMCA shows strong antifibrinolytic activity in vitro and in vivo by preventing the interaction of plasminogen and plasmin with lysine residues on the surface of fibrin (Dunn and Goa, 1999) . TAMCA is therefore widely used as an antifibrinolytic agent in cardiac surgery and in cases of uncontrolled bleeding of internal organs (Dunn and Goa, 1999) . TAMCA was initially also considered as an adjunct in the treatment of subarachnoid hemorrhages. However, experimental studies in the early 1980s showed that cortical application of TAMCA elicits epileptic seizures in cats (Yamaura et al., 1980; Pellegrini et al., 1982) . Moreover, clinical studies demonstrated that patients treated with TAMCA had a higher incidence of ischemic events than untreated patients (Guidetti and Spallone, 1981; Tsementzis et al., 1992) .
Renewed interest in the neurocompatibility of TAMCA was recently evoked by the licensing of a surgical glue containing TAMCA as an antifibrinolytic additive (Nur et al., 1998) .
Surgical glues based on human fibrin (fibrin sealants, FS) conventionally contain an antifibrinolytic additive to prevent premature clot destruction (Amrani et al., 2001) . FS are frequently used in neurosurgery for dural sealing, hemostasis, cranial nerve coating, and wrapping of nonclippable cerebral aneurysms. Thus, in view of the side effects mentioned above, FS containing TAMCA may represent a potential risk for patients undergoing surgery in or around the central nervous system. Indeed, Schlag et al. (2000) recently showed that an FS containing TAMCA causes hyperexcitability and severe convulsions when applied to the spinal cord of rats. Thus, TAMCA retains its convulsive property when incorporated into surgical glue. However, to date, nothing is known about the mechanisms underlying TAMCA-evoked convulsions.
In the present study, we addressed this question by performing receptor binding studies and in vivo experiments. Specifically, we focused on two neuronal receptors, which are involved in conditions of CNS hyperexcitability, the N-methyl-D-aspartate (NMDA) and the ␥-aminobutyric acid A (GABA A ) receptor. Application of either NMDA receptor agonists or GABA A receptor antagonists to the spinal cord of rats and mice has been shown to induce conThe first and second author contributed equally to this study.
vulsive behavior associated with increased nociception (Beitz and Larson, 1985; Nag and Riopelle, 1990; Zochodne et al., 1994; Ishikawa et al., 2000) . Here, we used rat brain membranes to study the influence of TAMCA on the binding of (Wong et al., 1988 801 is reduced by more than 60%. This allows for the investigation of the potential of TAMCA to substitute for one or both of these agonists. For NMDA receptor binding studies, adult Wistar rats were sacrificed by decapitation, the cortices were rapidly dissected, and rat cerebral cortices were homogenized in 50 mM Trisacetate buffer (pH 7.0). Membranes were isolated by centrifugation (Berger, 2000) and washed four times in 50 mM Tris-acetate buffer (pH 7.0), including a 10-min treatment with 0.02% Triton X-100 at 37°C. Membranes were stored at Ϫ70°C. [ 3 H]MK-801 (PerkinElmer Life Sciences; 5 nM, 23.9 Ci/mmol) was incubated with membranes at 23°C for 2 h in 10 mM Tris-acetate buffer, in the presence of 10 M glutamate and/or 10 M glycine and various concentrations of TAMCA (Sigma-Aldrich, St. Louis, MO). For nonspecific binding, glutamate and glycine were replaced by the respective antagonists D-2-amino-5-phosphonovaleric acid (100 M) and 5,7-dichlorokynurenic acid (10 M; both obtained from Tocris Cookson Ltd., Bristol, UK), resulting in a completely closed channel. The assay was terminated by filtration via a 48 places harvester (Brandel Inc., Gaithersburg, MD), using a Whatman GF/C glass fiber filter (Whatman Biometra GmbH, Niedersachsen, Germany) presoaked for 1 h in 0.3% polyethylenimine. After three washing steps, filters were transferred to counting vials, agitated for 1 h at 40°C in toluene-based liquid scintillation cocktail, and counted in a liquid scintillation counter.
[ 3 H]muscimol is a specific agonist of the GABA binding site of GABA A receptors (Krogsgaard-Larsen et al., 1997) . Therefore, its binding to this receptor is competitively inhibited by agonists and antagonists of the GABA binding site of GABA A receptors and allosterically modulated by many compounds interacting with other binding sites of this receptor. For binding experiments investigating [ 3 H]muscimol binding, adult Wistar rats were sacrificed by decapitation; the cortices were rapidly dissected and homogenized in 0.32 M sucrose containing 10 mM phosphate buffer, pH 7.4. The suspension was centrifuged at 1000g for 10 min at 4°C, and the supernatant was then centrifuged at 100,000g for 60 min. Membranes were resuspended in 50 mM Tris-citrate buffer, pH 7.4 (TC50) and stored at Ϫ70°C. To remove endogenous GABA, the suspension was thawed, washed in TC50, and frozen at Ϫ20°C. This procedure was repeated three times. Portions of membranes were then resuspended in TC50 and incubated in a total of 1 ml containing 5 nM [
3 H]muscimol (28.5 Ci/mmol; PerkinElmer Life Sciences, Boston, MA) and various concentrations of TAMCA (Sigma-Aldrich). Following 60-min incubation at 4°C, the membranes were filtered through Whatman GF/B filters, and the filters were rinsed with 3.5 ml of ice-cold TC50. Filters were transferred to scintillation vials and subjected to scintillation counting after addition of 3.5-ml Filter-Count (Packard Bioscience B.V., Groningen, The Netherlands) scintillation fluid. Nonspecific binding determined in the presence of 1 mM GABA was subtracted from total [ 3 H]muscimol binding, to result in specific binding. Dose-response curves were fitted (one site competition) using GraphPad Prism (GraphPad Software Inc., San Diego CA).
Culture and Transfection of HEK Cells. HEK cells were maintained in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (BioWhittaker Europe, Verviers, Belgium), 2 mM glutamine, 100 units ml Ϫ1 penicillin G and 100 g ml Ϫ1 streptomycin by using standard cell culture techniques. Exponentially growing HEK cells were dispersed using 0.25% trypsin and seeded at 1 ϫ 10 5 cells per 35-mm dish in 1.5 ml of culture medium. Cells were transfected with cDNAs encoding for rat ␣1␤2␥2 subunits (ratio 1:1:1) of GABA A receptors subcloned individually into pCI expression vectors (Promega Corp., Madison, WI), using the calcium phosphate precipitation method (Chen and Okayama, 1988) . A plasmid (pEGFP-N1; CLONTECH, Palo Alto, CA) encoding for the green fluorescent protein EGFP was cotransfected as a transfection marker.
Patch-Clamp Experiments. Patch-clamp experiments were performed at room temperature 1 to 2 days after transfection using the perforated patch technique (Rae et al., 1991) . We used single cells that were expressing EGFP (and thus presumably GABA A receptors) and that were not electrically coupled to other cells as judged visually and by cell capacitance (10 -25 pF). GABA and TAMCA were applied for 4 s in 60 s intervals using a DAD-12 superfusion system (ALA Scientific Instruments Inc., Westbury, NY). Extracellular solution contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 5 mM glucose, 10 mM HEPES, pH ϭ 7.4. The pipette solution contained 140 mM KCl, 11 mM EGTA, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 10 and 0.2 mg ml Ϫ1 amphotericin B (Sigma-Aldrich), pH ϭ 7.2. The cells were clamped at Ϫ60 mV; currents were filtered at 1 kHz, recorded using an Axopatch 200A amplifier (Axon Instruments Inc., Foster City, CA), and analyzed with Clampfit software (Axon Instruments). Dose-response curves were fitted (one-site competition) using GraphPad Prism (GraphPad Software Inc.).
In Vivo Experiments. The following two randomized studies were carried out: 1) a dose-response study and 2) a GABA A receptor ligand study. The model was the same for both and has been described in detail elsewhere (Schlag et al., 2000) . In brief, male rats (300 -400 g) were anesthetized with 100 mg/kg ketamine hydrochloride (Ketalar; Parke-Davis, Berlin, Germany) and 10 mg/kg xylazine hydrochloride (Rompun; Bayer, Leverkusen-Bayerwerk, Germany) followed by 0.3 mg/kg atropine (Nycomed Austria GmbH, Vienna, Austria). A laminectomy was carried out at T13 thereby exposing the fourth lumbar spinal cord segment. Additional anesthetic (30% of initial dose) was given shortly before application to ensure deep anesthesia. Following resection of the dura, a collagen sponge (TissuFleece E, Baxter AG, Vienna, Austria) soaked with the test solution was applied to the dorsal surface of the spinal cord. Hind limb (HL) hyperexcitability was assessed 10 min after application. The animals were euthanized thereafter. The experiments were conducted in accordance with the Declaration of Helsinki.
Tranexamic acid, muscimol (muscimol hydrobromide; Sigma-Aldrich), and bicuculline (bicuculline methobromide; Sigma-Aldrich) were dissolved in phosphate-buffered saline (PBS; pH 7.4). The working solutions of TAMCA and muscimol were kept at 6 to 8°C and used within 2 weeks. Bicuculline solution was made on the day of the experiment.
Experimental Groups. In the dose-response study, rats received collagen sponges soaked prior to application with 25 l of either vehicle (control; n ϭ 5) or a solution containing different concentra- jpet.aspetjournals.org tions of TAMCA [1, 2, 3, 4, or 5 mg/ml (corresponds to 6.25-31.25 mM); n ϭ 5 for each concentration]. In the GABA A receptor ligand study, the collagen sponges were soaked with 25 l of either vehicle (n ϭ 5), 5 mg/ml TAMCA (n ϭ 6), 5 mg/ml TAMCA and 0.1 mg/ml muscimol (n ϭ 5), or 1 mg/ml bicuculline, a specific GABA A receptor antagonist (n ϭ 5). For coapplication of TAMCA and muscimol, a solution containing 10 mg/ml TAMCA and a solution containing 0.2 mg/ml muscimol were mixed in equal parts immediately prior to application. We also carried out three experiments in which muscimol solution (0.1 mg/ml) was applied to rats with established hyperexcitability following the application of TAMCA solution (5 mg/ml).
Hind Limb Hyperexcitability. Hyperexcitability was assessed by evaluating the HL withdrawal reflex in response to noxious mechanical stimulation during anesthesia. The noxious stimuli were delivered to two distinct points on the fourth digit of each hind limb using a force-calibrated (on electronic balance) forceps (H. Gilly, General Hospital, Vienna, Austria). Stimulation was carried out at 30-s intervals to avoid hypersensitivity (Thalhammer et al., 1995) . The response was scored according to a semiquantitative scale (Table  1) . Concurrently, EMGs were recorded from the ipsilateral biceps femoris muscle via needle electrodes. EMGs were recorded with a NeuroMax (XLTEK, Oakville, ON, Canada) using the triggered recording mode with the trigger set at Ϯ30 V and stored on a personal computer for later analysis. EMG peak-to-peak amplitude, HL reflex score, and the stimulation force were evaluated.
Statistical Analysis. A one-way analysis of variance was used to test for differences between groups. Post hoc analysis was performed using the Student-Newman-Keuls t test for multiple comparisons. Linear regression analysis was performed to test the correlation of the concentration of TAMCA with the following parameters: EMG amplitude, HL reflex score, and applied force. Significance was set at p Ͻ 0.05. Unless noted otherwise, values represent means Ϯ standard deviation.
Results

Binding Studies. Specific binding of [
3 H]MK-801 to NMDA receptors crucially depends on the simultaneous presence of the coagonists glutamate and glycine. In the presence of saturating concentrations of both coagonists (i.e., with the NMDA channel fully opened) TAMCA up to a concentration of 10 mM had no influence on specific binding of [ 3 H]MK-801 to rat cortical membranes (not shown). Furthermore, concentrations of up to 3 mM TAMCA were not able to significantly compensate for the omission of either glycine or glutamate (Fig. 1) . Higher concentrations of TAMCA were not used in these experiments to avoid modulation of NMDA receptors by the amino acids glutamate and glycine that possibly are present in trace amounts in TAMCA.
Binding of the GABA binding site agonist [
3 H]muscimol to GABA A receptors present in membranes from rat cerebral cortex, however, was inhibited by TAMCA in a dose-dependent manner (Fig. 2A) . The IC 50 value was 2.1 Ϯ 0.2 mM (0.33 Ϯ 0.04 mg/ml, mean Ϯ S.D. of three experiments performed in triplicate and fitted by GraphPad Prism). These data indicate that TAMCA interacts with the GABA binding site of GABA A receptors.
Patch-Clamp Experiments. Patch-clamp experiments were then used to investigate the effects of TAMCA on the major GABA A receptor subtype composed of ␣1␤2␥2 subunits. Application of 30 M GABA to voltage-clamped ␣1␤2␥2 transfected HEK cells elicited currents that represented about 70% of the maximum GABA-induced currents in the respective cell. Currents could be completely blocked by 30 M bicuculline and are therefore solely caused by activation of GABA A receptors (experiments not shown). Coapplication of TAMCA at concentrations of 1, 3, 10, or 30 mM, dose dependently inhibited the current elicited by 30 M GABA as indicated by single current traces (Fig. 2B) . Averaged results from eight individual cells are shown in Fig. 2C . IC 50 of TAMCA for the inhibition of currents elicited by 30 M GABA was found to be 7.1 Ϯ 3.1 mM (1.12 Ϯ 0.49 mg/ml, jpet.aspetjournals.org mean Ϯ S.D. of eight cells separately fitted). Threshold concentrations of TAMCA for the inhibition of chloride currents elicited by 30 M GABA were 0.3-1 mM (0.047-0.157 mg/ ml). Inhibition of GABA currents by 30 mM TAMCA was fully reversed after a 60-s washout period, and no apparent effect of 30 mM TAMCA on GABA A receptors was seen in the absence of GABA (data not shown). Thirty micromolars (Ϫ) bicuculline methiodide (a known GABA A receptor antagonist) completely blocked currents elicited by 30 M GABA (data not shown). Currents measured in response to GABA are thus indeed caused by GABA A receptor activation. Further experiments indicated that a concentration of 10 mM (1.57 mg/ml) of TAMCA produced a rightward shift of the GABA dose-response curve of approximately one order of magnitude for GABA A receptors composed of ␣1␤2␥2 subunits, which resulted in significantly different EC 50 values (p ϭ 0.006, two-tailed unpaired Student's t test) (Fig. 2D ) without changing the maximum currents elicited by GABA. Thus, high concentrations of GABA were able to completely overcome the inhibitory effect of 10 mM TAMCA. This suggests that TAMCA competitively inhibited binding of GABA to the GABA binding site.
In Vivo Dose-Response Study. Rats in the control group showed no (n ϭ 3) or a very weak response (n ϭ 2) to pinch stimulation (reflex score, 0 -1; mean, 0.15) despite consistently high stimulation forces (mean Ϯ S.D., 1377 Ϯ 117 g).
Measurable EMGs were observed in one of the two rats that showed visible reflexes (mean, 60 V).
Hyperexcitability following application of TAMCA showed a clear dose dependence (Fig. 3, A and B) . Thus, pinch stimulation after application of 1 mg/ml (6.25 mM) TAMCA evoked a weak response of the ipsilateral HL in four/five rats (reflex scores, 1-2) whereas application of 5 mg/ml (31.25 mM) always elicited a bilateral response (reflex scores, 4 -6). Mean reflex scores and EMG amplitudes both increased significantly with increasing concentration of TAMCA (p Ͻ 0.001 for both parameters).
There was no significant relationship between the concentration of TAMCA and the mean force that elicited a response (p ϭ 0.24). However, significantly less force (mean Ϯ S.D., 676 Ϯ 342 g) was applied in those animals that had received TAMCA compared with the control animals (data not shown). In Vivo GABA A Receptor Ligand Study. In the control group, only one rat showed a very weak HL withdrawal reflex (reflex score, 1) without a concurrent EMG whereas the other four animals did not respond to pinch stimulation at all (reflex score, 0; Fig. 4, A and B) . Stimulation forces were consistently high (mean Ϯ S.D., 1116 Ϯ 29 g).
Application of either TAMCA (5 mg/ml; 31.25 mM) or bicuculline (1 mg/ml) resulted in strong HL hyperexcitability that was characterized by high reflex scores (Fig. 4A ) and large EMG amplitudes (Fig. 4B) . Low stimulation forces were required to elicit a response (TAMCA, 462 Ϯ 284 g; bicuculline, 300 Ϯ 28 g).
Coapplication of TAMCA (5 mg/ml; 31.25 mM) with muscimol (0.1 mg/ml) completely blocked HL hyperexcitability (reflex scores, 0; Fig. 4A ) and no measurable EMGs were observed in any of the five rats. Mean stimulation force was not significantly different from that in the control group (1133 Ϯ 124 g versus 1116 Ϯ 29 g). Application of muscimol (0.1 mg/ml) 5 to 10 min following TAMCA (5 mg/ml; 31.25 mM) also abolished HL hyperexcitability (data not shown).
Discussion
In the present study, we investigated possible neuropharmacological basis for the convulsions elicited by a topical application of TAMCA to the nervous system. We demonstrated that TAMCA did not influence binding of In patch-clamp experiments, TAMCA did not induce currents in HEK cells expressing GABA A receptors composed of ␣1␤2␥2 subunits but was able to inhibit GABA-induced currents in these cells. TAMCA seems to competitively rather than allosterically interact with GABA at GABA A receptors, because high concentrations of GABA were able to completely reverse the inhibitory effect of 10 mM TAMCA. A negative allosteric interaction of TAMCA with GABA A receptors, however, cannot entirely be excluded. The exact type of interaction of TAMCA with GABA A receptors was not further investigated because it was not important for the conclusions of this paper.
In in vivo experiments, application of TAMCA to the spinal cord of rats induced hyperexcitability that could be blocked by muscimol. Moreover, the hyperexcitability that developed after application of the specific GABA A receptor antagonist bicuculline resembled that after application of TAMCA. We can only speculate which neurons within the spinal cord were affected by TAMCA. Due to the site of application, neurons within the superficial lamina (I-IV) of the dorsal horns were most likely exposed to the highest concentrations of this compound. Within the lumbar spinal cord, these lamina are the principal termination sites of cutaneous afferent fibers from the hind limb and contain many neurons associated with nociception (Grant, 1995; Willis et al., 1995) . It has been postulated that incoming signals are processed and encoded within lamina I-IV and that interfering with this modulation will cause aberrant nociception to occur (Hwang and Yaksh, 1997) .
The hyperexcitability seen in this study represented a hyperalgesic condition (i.e., a situation where painful stimuli are perceived stronger than under normal conditions). However, TAMCA has been shown to induce effects other than hyperalgesia. In a previous study, we applied high concentrations of TAMCA (157-318 mM ϭ 10 -50 mg/ml) in fibrin sealant to the lumbar spinal cord of rats (Schlag et al., 2000) , because one of the commercial fibrin sealants contains 49 mg/ml TAMCA. Immediately after application of TAMCA containing fibrin sealants, all rats developed local hyperalgesia, but some also responded with HL withdrawal after non-noxious stimulation, a feature typical for allodynia (Hwang and Yaksh, 1997; Ishikawa et al., 2000) . Moreover, all rats developed spontaneous local and generalized convulsions within 30 min after application. A concentration of Ϸ10 to 50 mg/ml of TAMCA is needed in fibrin sealants to prevent early lysis in vivo, if no aprotinin is used. In vivo effects of TAMCA in fibrin sealants were observed at concentrations as low as 1 mg/ml (data not shown).
These earlier observations suggested that TAMCA might have a nonspecific excitatory effect on spinal motor activity since similar effects have been seen after spinal application Fig. 4 . A, HL withdrawal reflex scores after application of vehicle (PBS; pH 7.4), TAMCA (5 mg/ml ϭ 31.8 mM), TAMCA with muscimol (Mus; 0.1 mg/ml), or bicuculline (Bic; 0.1 mg/ml); muscimol completely prevented TAMCA-induced hyperexcitability whereas hyperexcitability after bicuculline application was similar to that seen in the TAMCA group. B, biceps femoris EMG amplitudes. Same groups as Fig. 4A . Note complete absence of EMGs in the control (PBS) and the muscimol groups. jpet.aspetjournals.org of excitatory amino acids such as NMDA or kainic acid (Aanonsen and Wilcox, 1987; Gimenez-Llort et al., 1998) . Direct neuronal damage may also have contributed to these dramatic effects seen in vivo because similar high concentrations of TAMCA (Ͼ153 mM ϭ 24 mg/ml) have been shown to induce neuronal damage in vitro in less than 4 h (B. Tawil, unpublished data). Nevertheless, we believe that both the nociceptive and the convulsive effects of spinal application of high concentrations of TAMCA are based on the blockage of GABA-dependent inhibition within the spinal cord. This is further supported by the observation that spinal application of the GABA A receptor antagonist bicuculline can evoke allodynia as well as strong generalized seizures depending on its dose (Beitz and Larson, 1985; Ishikawa et al., 2000) . Squires et al. (1988) and Chang and Gao (1995) Yamaura et al. (1980) that i.v. application of high amounts of ⑀-amino caproic acid elicits epileptic brain activity in cats.
In conclusion, our studies suggest that TAMCA induces convulsions by blocking GABA-mediated inhibition in the CNS. Thus, application of fibrin sealants containing TAMCA or other structurally similar analogs, but not aprotinin as an antifibrinolytic additive, poses a risk for patients undergoing neurosurgery.
